dj Orthopedics Announces Pricing of 7.5 Million Share Public Offering
SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- dj Orthopedics, Inc., (NYSE: DJO), today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $19.00 per share. dj Orthopedics is offering 2,750,000 shares and selling stockholders are offering 4,750,000 shares through a prospectus supplement pursuant to the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission. The offering will result in estimated net proceeds to dj Orthopedics of approximately $49 million. The Company will not receive any of the net proceeds of the sale of shares by the selling stockholders. In addition, dj Orthopedics and certain of the selling stockholders have granted the underwriters an option to purchase up to an additional 1,125,000 shares of common stock within 30 days after the offering to cover any over-allotments, if any.
J.P. Morgan Securities Inc. and Lehman Brothers Inc. are joint book- running managers for the offering. Co-managers of the offering are Piper Jaffray & Co., Wachovia Capital Markets, LLC, First Albany Capital Inc. and WR Hambrecht + Co, LLC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Copies of the final prospectus supplement and the prospectus related to the offering can be obtained from J.P. Morgan Securities Inc., One Chase Manhattan Plaza, Floor 5B, New York, New York 10081 and from Lehman Brothers Inc., c/o ADP Financial Services Prospectus Fulfillment, 1155 Long Island Avenue, Edgewood, New York 11717.
About dj Orthopedics, Inc.
dj Orthopedics is a global medical device company specializing in rehabilitation and regeneration products for the non-operative orthopedic and spine markets. The Company's broad range of over 600 rehabilitation products, including rigid knee braces, soft goods and pain management products, are used to prevent injury, to treat chronic conditions and to aid in
recovery after surgery or injury. The Company's regeneration products consist of bone growth stimulation devices that are used to treat nonunion fractures and as an adjunct therapy after spinal fusion surgery.
The Company sells its products in the United States and in more than 30 other countries through networks of agents, distributors and its direct sales force that market its products to orthopedic and spine surgeons, podiatrists, orthopedic and prosthetic centers, third-party distributors, hospitals, surgery centers, physical therapists, athletic trainers and other healthcare professionals.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements relate to, among other things, the Company's financing plans. These forward-looking statements are based on the Company's current expectations and are subject to a number of risks, uncertainties and assumptions, such as stock market price fluctuations and those risks detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward- looking statements, whether as a result of new information, future events or otherwise.
SOURCE dj Orthopedics, Inc.
-0- 02/19/2004
CO: dj Orthopedics, Inc.; J.P. Morgan Securities Inc.; Lehman Brothers Inc.;
Piper Jaffray & Co.; Wachovia Capital Markets, LLC; First Albany Capital
Inc.; WR Hambrecht + Co, LLC
ST: California
IN: HEA MTC BIO
SU: OFR
LP
-- LATH042 --
2947 02/19/2004 07:55 EST http://www.prnewswire.com
Company Investor/Media Contact:
DJO Incorporated
Mark Francois
Director of Corporate Communications & Investor Relations
760-734-4766
